Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with end stage renal disease who are receiving a stable hemodialysis regimen (3 times per week) with sufficient dialysis adequacy;~* Serum phosphorus level range from \>1.94 mmol/L (6.0 mg/dL) to ≤3.23 mmol/L (10.0 mg/dL) at the end of washout phase.~Exclusion Criteria:~* Kidney transplant patient or scheduled kidney transplant, or change to peritoneal dialysis, home hemodialysis or plan to relocate to another dialysis center during the study period；~* Serum phosphorus level is \<1.29 mmol/L（4.0 mg/dL) or \>2.42 mmol/L（7.5 mg/dL) at screening, or documented to be \>3.23 mmol/L（10 mg/dL) within the latest three month prior to screening (screening included);~* Serum calcium level is \<8 mg/dL or \>11 mg/dL at the screening;~* Serum immunoreactive parathyroid hormone (iPTH)\>1000 pg/mL at the screening;~* History of hemochromatosis or serum ferritin value ≥1000 μg/L at screening；~* Current clinically significant gastrointestinal (GI) disorder, or history of intestine obstruction, gastrectomy or duodenectomy, or GI tract surgery within 12 weeks prior to screening;~* Poorly controlled hypertension, cardiovascular disorders, and history of cerebrovascular disease or cardiovascular disease event within 24 weeks (6 months) prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VS-505 500mg (Type: EXPERIMENTAL): VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
- VS-505 750mg (Type: EXPERIMENTAL): VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
- VS-505 1500mg (Type: EXPERIMENTAL): VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
- VS-505 2250mg (Type: EXPERIMENTAL): VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
- Sevelamer Carbonate 1600mg (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).